Small Biotech that fail to secure a deal before or

Quote:

---

Small Biotech that fail to secure a deal before or on approval are especially risky to hold , because revenue is always slow to materialise ,and costs of launching a drug in competition with big pharma are too great.

---

We are in a unique situation. COVID-19 will be approved before HIV. COVID-19 will be in large demand with no selling on our part needed. We don't need Vyera and their 50% cut. The only thing we'll need is a distribution channel.

If the federal lawsuit kills Vyera to the point they can't make milestone payments all the better. We'll then take back the HIV indication. The money from COVID-19 would then allow us to go forward in any way we chose.